Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Pomerantz Law Firm has initiated investigations into potential securities fraud and unlawful business practices at Twenty One Capital, Inc., United Homes Group, Inc., and Trip.com Group Limited. Investors who suffered losses are encouraged to join class action lawsuits against these companies.
05/05/2026, 5:00 PM • GlobeNewswire
The Schall Law Firm is investigating Twenty One Capital, Inc. (NYSE: XXI) for potential securities law violations, including allegations of false or misleading statements and failure to disclose material information to investors. Shareholders who suffered losses are encouraged to participate in the investigation.
04/26/2026, 9:58 PM • GlobeNewswire
Immatics Announces $125 Million Underwritten Offering
Immatics N.V. plans to sell 12.5 million ordinary shares at $10.00 per share, expecting to raise $125 million in a public offering managed by Jefferies, Leerink Partners, and Cantor.
12/05/2025, 6:00 AM • GlobeNewswire
Inhibikase Therapeutics is conducting a public offering of common stock and pre-funded warrants, raising approximately $100 million to support its clinical-stage pharmaceutical development for pulmonary arterial hypertension.
11/20/2025, 9:54 PM • GlobeNewswire
Invivyd Announces Pricing of $125 Million Public Offering of Common Stock and Pre-Funded Warrants
Invivyd is conducting a public offering of 44 million common stock shares and 6 million pre-funded warrants at $2.50 per share, expecting to raise approximately $125 million to fund commercial preparedness, research and development, and corporate purposes.
11/17/2025, 10:40 PM • GlobeNewswire
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential drug commercialization and research efforts.
10/21/2025, 12:14 AM • Benzinga
Disc Medicine has priced a public offering of common stock and pre-funded warrants, expecting to raise approximately $225 million to support potential commercialization of bitopertin and fund research and development.
10/21/2025, 12:14 AM • GlobeNewswire
Zealand Pharma to participate in upcoming investor conferences in September 2025
Zealand Pharma will participate in multiple healthcare investor conferences in September 2025, with key executives hosting meetings and participating in fireside chats across events in Zürich, New York, Boston, London, and Brussels.
08/28/2025, 11:00 AM • GlobeNewswire
Compass Therapeutics to Participate in Upcoming September Investor Events
Compass Therapeutics will participate in multiple healthcare and investment conferences in September 2025, including events in Boston and New York, presenting their oncology-focused antibody-based therapeutics research.
08/26/2025, 8:00 AM • GlobeNewswire
